ES2314931T3 - Utilizacion de 3,11b-cis-dihidrotetrabenazina para el tratamiento de sintomas de la enfermedad de huntington. - Google Patents

Utilizacion de 3,11b-cis-dihidrotetrabenazina para el tratamiento de sintomas de la enfermedad de huntington. Download PDF

Info

Publication number
ES2314931T3
ES2314931T3 ES06764942T ES06764942T ES2314931T3 ES 2314931 T3 ES2314931 T3 ES 2314931T3 ES 06764942 T ES06764942 T ES 06764942T ES 06764942 T ES06764942 T ES 06764942T ES 2314931 T3 ES2314931 T3 ES 2314931T3
Authority
ES
Spain
Prior art keywords
compound
dihydrotetrabenazine
isomer
cis
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06764942T
Other languages
English (en)
Spanish (es)
Inventor
Robert Cambridge Laboratories Limited TRIDGETT
T. Filloux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Laboratories Ireland Ltd
Original Assignee
Cambridge Laboratories Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Laboratories Ireland Ltd filed Critical Cambridge Laboratories Ireland Ltd
Application granted granted Critical
Publication of ES2314931T3 publication Critical patent/ES2314931T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES06764942T 2005-07-14 2006-07-13 Utilizacion de 3,11b-cis-dihidrotetrabenazina para el tratamiento de sintomas de la enfermedad de huntington. Expired - Lifetime ES2314931T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0514501 2005-07-14
GBGB0514501.6A GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ES2314931T3 true ES2314931T3 (es) 2009-03-16

Family

ID=34897233

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06764942T Expired - Lifetime ES2314931T3 (es) 2005-07-14 2006-07-13 Utilizacion de 3,11b-cis-dihidrotetrabenazina para el tratamiento de sintomas de la enfermedad de huntington.

Country Status (23)

Country Link
US (1) US20080319000A1 (enExample)
EP (2) EP1885363B1 (enExample)
JP (1) JP2009501202A (enExample)
KR (1) KR20080030666A (enExample)
CN (1) CN101282726A (enExample)
AT (2) ATE409481T1 (enExample)
AU (1) AU2006268098B2 (enExample)
CA (1) CA2615077A1 (enExample)
CY (1) CY1108653T1 (enExample)
DE (1) DE602006002982D1 (enExample)
DK (1) DK1885363T3 (enExample)
ES (1) ES2314931T3 (enExample)
GB (1) GB0514501D0 (enExample)
HR (1) HRP20080677T3 (enExample)
ME (1) ME01629B (enExample)
NZ (1) NZ565522A (enExample)
PL (1) PL1885363T3 (enExample)
PT (1) PT1885363E (enExample)
RS (1) RS50626B (enExample)
RU (1) RU2409365C2 (enExample)
SI (1) SI1885363T1 (enExample)
WO (1) WO2007007105A1 (enExample)
ZA (1) ZA200800905B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
CN110691596A (zh) * 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US12144899B2 (en) 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) * 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
KR20220066253A (ko) 2019-07-16 2022-05-24 러쉬 유니버시티 메디컬 센터 신경퇴행성 장애를 치료하기 위한 벤조에이트 함유 조성물의 용도

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009918A (en) * 1961-11-21 Chz ch
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US3132147A (en) * 1964-05-05
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3123609A (en) * 1964-03-03 Benzo
US3159638A (en) * 1964-12-01 Xcha-chj
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US2843591A (en) * 1958-07-15 Method for preparing same
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
JPS4836303B1 (enExample) * 1968-12-27 1973-11-02
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU591152B2 (en) * 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
BR0110302A (pt) * 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
AU2006268098A1 (en) 2007-01-18
EP2027861B1 (en) 2011-08-31
NZ565522A (en) 2010-04-30
RU2008105590A (ru) 2009-08-20
JP2009501202A (ja) 2009-01-15
CY1108653T1 (el) 2014-04-09
ATE522215T1 (de) 2011-09-15
KR20080030666A (ko) 2008-04-04
DK1885363T3 (da) 2008-12-08
RS50626B (sr) 2010-06-30
HK1111085A1 (en) 2008-08-01
EP1885363B1 (en) 2008-10-01
EP2027861A1 (en) 2009-02-25
SI1885363T1 (sl) 2009-02-28
WO2007007105A1 (en) 2007-01-18
PL1885363T3 (pl) 2009-05-29
EP1885363A1 (en) 2008-02-13
CA2615077A1 (en) 2007-01-18
ME01629B (me) 2010-06-30
CN101282726A (zh) 2008-10-08
GB0514501D0 (en) 2005-08-24
ZA200800905B (en) 2010-04-28
PT1885363E (pt) 2009-01-08
RU2409365C2 (ru) 2011-01-20
HRP20080677T3 (hr) 2009-02-28
DE602006002982D1 (de) 2008-11-13
US20080319000A1 (en) 2008-12-25
AU2006268098B2 (en) 2011-02-17
ATE409481T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
ES2313292T3 (es) Dihidrotetrabenazinas y composiciones farmaceuticas que las contienen .
RU2409365C2 (ru) ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА ДЛЯ ЛЕЧЕНИЯ СИМПТОМОВ БОЛЕЗНИ ГЕНТИНГТОНА
EP3503879B1 (en) Composition comprising (a) a dual agent acting as a 5-ht2a receptor antagonist and cyp2d6 inhibitor and (b) an nmda receptor antagonist for use in the treatment of diseases involving glucose
RU2771164C2 (ru) (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства
ES2318771T3 (es) 3,11b-cis-dihidrotetrabenazinas para el tratamiento de la esquizofrenia y otras psicosis.
TW202216705A (zh) 取代哌啶化合物及其用途
ES2609264T3 (es) Formas sólidas que comprenden (-)-O-desmetilvenlafaxina y usos de las mismas
CN118974044A (zh) 化合物
ES2317564T3 (es) 3,11b.cis.dihidrotetrabenazina para el tratamiento de enfermedades proliferativas o inflamaciones.
ES2607184T3 (es) Inhibidores de la enzima fosfodiesterasa 10
CA3229907A1 (en) Deuterated empathogens
US20230373940A1 (en) Carboxylic diarylthiazepineamines and uses thereof
AU2012250776B2 (en) Pentylenetetrazole derivatives
CN115925699A (zh) 具有镇痛活性的稠环化合物及其制备方法与用途
KR20150115809A (ko) 이소메텝텐 이성질체
CN121568919A (zh) 不对称苯烷基胺
CN120513239A (zh) 作为血清素能剂用于治疗相关病症的吲哚啉衍生物
HK1111085B (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease
HK1121972A (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington's disease
WO2025030181A1 (en) Crystalline polymorphs of 4-bromo-2,5-dimethoxyphenethylamine (2c-b)
KR20070023666A (ko) 디하이드로테트라베나진 및 이를 함유하는 약학 조성물